Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
SP Industries, Inc., a leading designer and manufacturer of state-of-the-art laboratory equipment, pharmaceutical fill-finish manufacturing solutions, laboratory supplies and glassware, announced that it has acquired the assets of privately held i-Dositecno.
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
This marks the eighth such extension for the deal.
Edan Diagnostics, Inc., a wholly own subsidiary of Edan Instruments, Inc., a world leader in the development and manufacture of bio-electronic devices and laboratory analyzers for medical diagnostics, and LGC, a global life science tools leader, announced today the sale of LGC’s ClariLight molecular diagnostics POC platform to Edan.
Founder Mike Wenger to Join Staff as Vice President of Patient Engagement
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
Innovative approach for hard-to-treat cancers being developed at the Cancer Research UK Beatson Institute
CELLINK publishes the quarterly report for the period 1st of June 2019 – 31st of August 2019 and for the full year of operations 2018-2019.
BioArctic and Eisai presented new data regarding BAN2401 at the Alzheimer’s Association International Conference® (AAIC®) in July that confirmed BAN2401’s unique characteristics and was consistent with previously presented results
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced third quarter revenue and net cash position as of September 30, 2019.